Zentek (Zentek) ROCE % : -45.40% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Zentek ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zentek's annualized ROCE % for the quarter that ended in Dec. 2023 was -45.40%.

Zentek ROCE % Historical Data

The historical data trend for Zentek's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentek ROCE % Chart

Zentek Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-10.35

-6.14

-15.18

-89.57

-37.13

Zentek Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-46.17	-37.90	-42.51	-49.03	-45.40

Zentek ROCE % Calculation

Zentek's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-10.447	/	( ( (35.533 - 1.821)	+	(24.329 - 1.769) )	/ 2 )
	=	-10.447	/	( (33.712	+	22.56)	/ 2 )
	=	-10.447	/	28.136
	=	-37.13 %

Zentek's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-8.224	/	( ( (20.307 - 1.397)	+	(18.506 - 1.189) )	/ 2 )
	=	-8.224	/	( ( 18.91	+	17.317 )	/ 2 )
	=	-8.224	/	18.1135
	=	-45.40 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Zentek (NAS:ZTEK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zentek ROCE % Related Terms

Thank you for viewing the detailed overview of Zentek's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zentek (Zentek) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zentek Ltd (NAS:ZTEK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ZAY0:Germany ZEN:Canada

Address

24 Corporate Ct, Guelph, ON, CAN, N1G 5G5

Website

https://www.zentek.com

Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment.?It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19,?and the potential to use?similar?compounds?as pharmaceutical products?against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.